AMAmanda Rae Maxwell

Amanda Rae Maxwell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amanda Rae Maxwell has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Addis Yilma

    Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    1 shared publication
  • Alannah D. Taylor

    W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

    1 shared publication
  • Darla Quijada

    Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    1 shared publication
  • Elisa M. Rouse Salcido

    Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    1 shared publication
  • Eric K. Hutchinson

    Office of Laboratory Animal Medicine, University of Delaware, Newark, DE 19716, USA

    1 shared publication
  • Eric Kenneth Hutchinson

    Department of Molecular and Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

    1 shared publication

Latest Publications

  • Open Access

    In vivo photoacoustic imaging of swine ureters injected with methylene blue

    by Junior Arroyo, Junhao Zhang, Jiaxin Zhang, Nethra Venkatayogi, Manik Kakkar, Amanda Maxwell, Kathleen Gabrielson, Muyinatu A. Lediju Bell

    SignificanceUreteral injuries represent a major concern during a range of surgical procedures, due to the proximity of the ureter to target surgical structures. Intraoperative identification of the ureter is critical to prevent this accidental damage.AimWe demonstrate the first known in vivo photoacoustic imaging of the ureter in swine following intravenous administration of FDA-approved methylene blue, enabled by a software-hardware integration that has not been previously reported in the literature.ApproachPhotoacoustic channel data from the ureters of two swine were acquired using a Vevo F2 ultrasound system and an Opotek Phocus Mobile laser. Images were beamformed using a delay-and-sum algorithm. Photoacoustic image quality was evaluated using contrast, signal-to-noise ratio (SNR), and generalized contrast-to-noise ratio (gCNR) metrics, measured 10 to 80 min after methylene blue injection.ResultsAcross the 10- to 80-min imaging window, median contrast (3.46–11.43 dB), SNR (2.84–6.99), and gCNR (0.27–0.64) confirmed sustained ureter visibility with methylene blue. Maximum image quality was observed 20- to 30-min after methylene blue injection, with significantly higher contrast, SNR, and gCNR values compared with earlier or later time points (p<0.05).ConclusionsIn vivo results demonstrate that methylene-blue-enhanced photoacoustic imaging can visualize the ureter over a time duration that is consistent with the length of surgical procedures, providing initial feasibility for real-time photoacoustic-guided surgery applications.


  • Open Access

    Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models

    by Styliani Karanika, Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James T. Gordy, Hannah Bailey, Darla Quijada, Kaitlyn Fessler, Rokeya Tasneen, Elisa M. Rouse Salcido, et al.

    Mycobacterium tuberculosis remains a global health crisis, ranking among the deadliest infectious diseases worldwide. In response to the WHO’s call for therapeutic vaccines to complement antibiotic regimens and reduce tuberculosis (TB) treatment duration, we developed an intranasal DNA vaccine fusing the M. tuberculosis stringent response gene relMtb with the gene encoding the DC-targeting chemokine Mip3a (also known as CCL20 ). Administered alongside the first-line regimen, this vaccine accelerated a stable cure in immunocompetent murine TB models, reducing lung inflammation and eliciting robust and sustained RelMtb-stimulated T cell responses systemically and locally. The Mip3a/relMtb vaccine enhanced DC recruitment, activation, and spatial coordination with T cells, suggesting improved innate-adaptive immune synergy. Notably, it augmented the efficacy of a novel drug-resistant TB regimen as well. Critically, the vaccine induced analogous antigen-stimulated T cell immunity in nonhuman primates, the gold standard for preclinical TB vaccine evaluation, with responses detected in blood and bronchoalveolar lavage mirroring those observed in the murine models. These findings underscore the potential of this strategy to advance therapeutic TB vaccine development targeting M. tuberculosis persisters while providing a framework to define correlates of vaccine-mediated protection.

  • Open Access

    Collaborating for the Successful Retirement and End-of-Life Care of Non-Human Primates in Biomedical Research

    by Amanda R. Maxwell, Eric K. Hutchinson, Jaclyn V. Allen, Melissa C. Painter, Lydia M. Hopper

    Research facilities have established animal adoption programs for laboratory animals. However, adoption to private owners is not an option for non-human primates (NHPs), so their post-research life presents a unique challenge. Here, we describe a collaborative effort between laboratory animal veterinarians and behavioral management staff in retiring NHPs in place to ensure their quality of life after the completion of research projects. The success of our retirement program hinges on our collaborative efforts to manage clinical diseases such as arthritis, amyloidosis, and diarrhea; to surgically ex-plant previous research hardware; and to evaluate the animals’ behavior and temperament to ensure each individual is placed in a new group or living situation in which they are likely to be successful and to have good welfare. Implementation of a quality-of-life assessment tool for all retired animals allows all staff involved in the animals’ care to proactively and periodically assess the quality of life of these animals. The successful retirement of NHPs living in social groups is rewarding for all personnel and promotes a culture of caring. Research animal retirement is an important way for us to give back and honor the contributions these animals have made to advancing medicine.


  • Open Access

    A comparison of different antibiotic regimens for the treatment of naturally acquired shigellosis in rhesus and pigtailed macaques (Macaca mulatta and nemestrina)

    by Amanda Rae Maxwell, Jessica Ann Herrod, Eric Kenneth Hutchinson

    Background: Shigella spp. are common enteric pathogens in captive non‐human primates. Treatment of symptomatic infections involves supportive care and antibiotic therapy, typically with an empirical choice of antibiotic.Methods: Twenty‐four clinically ill, Shigella PCR‐positive animals were randomly assigned to one of four treatment groups: single‐dose ceftiofur crystalline free acid (CCFA), single‐dose azithromycin gavage, a 5‐day tapering azithromycin dose, or 7‐day course of enrofloxacin. We hypothesized that all antimicrobial therapies would have similar efficacy.Results: Animals in all groups cleared Shigella, based on fecal PCR, and had resolution of clinical signs 2 weeks after treatment. Eight out of nine clinically ill and PCR‐positive animals tested negative by fecal culture.Conclusions: Single‐dose CCFA, single‐dose azithromycin, and a 5‐day tapering course of azithromycin all performed as well as a 7‐day course of enrofloxacin in eliminating Shigella infection. Fecal PCR may be a better diagnostic than culture for Shigella.